Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 178

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 178
---
 item.

ITEM 4. Controls and Procedures. Disclosure
Controls and Procedures 

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, have
evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
the Exchange Act) as of March 31, 2025. Based on that evaluation, the Company’s Chief Executive Officer and the Company’s
Chief Financial Officer have concluded that as of March 31, 2025, due to the existence of the material weakness in the Company’s
internal control over financial reporting described below, the Company’s disclosure controls and procedures were not effective.

Management is responsible for establishing and
maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief
Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used
the framework set forth in the report entitled “Internal Control-Integrated Framework (2013)” published by the Committee of
Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based
on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.

Our management concluded that as of March 31, 2025,
our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas:

(1)we do not employ full time
in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine
transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from
third-party experts and/or consultants to gain a thorough understanding of these transactions;

(2)we have inadequate segregation
of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes,
and the performance of account reconciliations and approval; and

(3)we have ineffective controls
over the period end financial disclosure and reporting process caused by insufficient accounting staff.

Limitations on Effectiveness of Controls and
Procedures

In
designing and evaluating the disclosure controls and procedures and internal